Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inex/Enzon Marqibo to ODAC

Executive Summary

FDA's Oncologic Drug Products Advisory Committee will review Inex/Enzon's liposomal vincristine formulation Marqibo (formerly Onco TCS) Dec. 1, firms announce. Sponsors seek third-line monotherapy indication for treatment of relapsed aggressive non-Hodgkin's lymphoma. FDA lists Dec. 1 and 2 as tentative ODAC meeting dates. [Editor's Note: For more information, visit 1FDAAdvisoryCommittee.com]...

You may also be interested in...



Berlex Bonefos review

FDA's Oncologic Drugs Advisory Committee will discuss Berlex' NDA (21-776) for Bonefos (clodronate) as an adjuvant treatment for the reduction of occurrence of bone metastases in Stage II/III breast cancer patients on Dec. 2. Bonefos has an estimated user fee deadline of March 9, 2005. The committee will also review Ilex/Enzon's liposomal vincristine formulation Marqibo NDA (21-600) for relapsed aggressive non-Hodgkin's lymphoma and Ilex' Clolar (clofarabine) NDA (21-673) for pediatric patients (1-21 years) with refractory or relapsed acute leukemias on Dec. 1 (1"The Pink Sheet" Oct. 4, 2004, In Brief). The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m. on Dec. 1 and 8:30 a.m. on Dec. 2. [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.

EU Regulatory Roundup, September 2020: Uncharacteristically Slow As COVID-19/Brexit Wreak Havoc

European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has given EU and UK medtech stakeholders enough to ponder.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel